Fidelity Investments
VINC

Fidelity Investments’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Fidelity Investments’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– -$7 – 5782
2023
Q4 		– Hold
0
– – – 5356
2023
Q3 		– Hold
0
– – – 5220
2022
Q2 		– Sell
-23
Closed -$2K – 5593
2022
Q1 		$2K Buy
+23
New +$2.84K ﹤0.01% 4727

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments's VINC Position: Q1 2024 in Review

Fidelity Investments held its Vincerx Pharma, Inc. Common Stock (VINC) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5782.

Fidelity Investments first reported a position in VINC in Q1 2022 and has held it in 1 quarter since. The position peaked at $2K in Q1 2022. 40 funds tracked by Wall St. Rank hold VINC as of Q1 2024.

  • Fidelity Investments held 0 shares of Vincerx Pharma, Inc. Common Stock worth $0 as of Q1 2024.
  • Fidelity Investments left its Vincerx Pharma, Inc. Common Stock share count unchanged in Q1 2024.
  • Vincerx Pharma, Inc. Common Stock made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2024, its #5782 holding.
  • Fidelity Investments first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2022 and has held it in 1 quarter since.
  • Fidelity Investments's Vincerx Pharma, Inc. Common Stock position peaked at $2K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.